Geron was the scammiest of scammy mainstreamed cell therapy stocks with a nonsense trial but it had massive coverage. You’re right, and all of the analysts were absolute idiots.
Their follow-on drug that has nothing to do with the reason the company was created, seems to have more potential but given the history, if some analysts are still trying to save their reputations from when they showed they had absolutely no idea what they were talking about. I would not be surprised. I don’t know when they got delisted, so often analysts stick around waiting for a re-listing.
But I did not see immense coverage or actually any coverage with a superficial visit to Yahoo’s web app.
You waste everyone’s time with these dumb arguments. I do wish GERN well. But their original trial for their cell therapy had not a chance in hell of ever even vaguely validating their original treatment and they were pumped by numerous top, very bad, analysts.
Market Data 
Markets 
AI
